Surrogate outcomes: experiences at the Common Drug Review View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-12

AUTHORS

Angela Rocchi, Shoghag Khoudigian, Rob Hopkins, Ron Goeree

ABSTRACT

BACKGROUND: Surrogate outcomes are a significant challenge in drug evaluation for health technology assessment (HTA) agencies. The research objectives were to: identify factors associated with surrogate use and acceptability in Canada's Common Drug Review (CDR) recommendations, and compare the CDR with other HTA or regulatory agencies regarding surrogate concerns. METHODS: Final recommendations were identified from CDR inception (September 2003) to December 31, 2010. Recommendations were classified by type of outcome (surrogate, final, other) and acceptability of surrogates (determined by the presence/absence of statements of concern regarding surrogates). Descriptive and statistical analyses examined factors related to surrogate use and acceptability. For thirteen surrogate-based submissions, recommendations from international HTA and regulatory agencies were reviewed for statements about surrogate acceptability. RESULTS: Of 156 final recommendations, 68 (44%) involved surrogates. The overall 'do not list' (DNL) rate was 48%; the DNL rate for surrogates was 41% (p = 0.175). The DNL rate was 64% for non-accepted surrogates (n = 28) versus 25% for accepted surrogates (odds ratio 5.4, p = 0.002). Clinical uncertainty, use of economic evidence over price alone, and a premium price were significantly associated with non-accepted surrogates. Surrogates were used most commonly for HIV, diabetes, rare diseases, cardiovascular disease and cancer. For the subset of drugs studied, other HTA agencies did not express concerns for most recommendations, while regulatory agencies frequently stated surrogate acceptance. CONCLUSIONS: The majority of surrogates were accepted at the CDR. Non-accepted surrogates were significantly associated with clinical uncertainty and a DNL recommendation. There was inconsistency of surrogate acceptability across several international agencies. Stakeholders should consider collaboratively establishing guidelines on the use, validation, and acceptability of surrogates. More... »

PAGES

31

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1478-7547-11-31

DOI

http://dx.doi.org/10.1186/1478-7547-11-31

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1028671719

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24341379


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Axia Research, 2068 Waterbridge Drive, L7M 3W2, Burlington, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rocchi", 
        "givenName": "Angela", 
        "id": "sg:person.01151361731.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151361731.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McMaster University", 
          "id": "https://www.grid.ac/institutes/grid.25073.33", 
          "name": [
            "McMaster University, Hamilton, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khoudigian", 
        "givenName": "Shoghag", 
        "id": "sg:person.01001154670.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001154670.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Programs for Assessment of Technology in Health Research Institute", 
          "id": "https://www.grid.ac/institutes/grid.452761.3", 
          "name": [
            "PATH Research, Hamilton, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hopkins", 
        "givenName": "Rob", 
        "id": "sg:person.01245231275.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245231275.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Programs for Assessment of Technology in Health Research Institute", 
          "id": "https://www.grid.ac/institutes/grid.452761.3", 
          "name": [
            "PATH Research, Hamilton, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goeree", 
        "givenName": "Ron", 
        "id": "sg:person.01052355256.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052355256.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/jama.2012.7961", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000247836"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1377/hlthaff.25.2.337", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004154780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2009.1409", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009725452"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa072761", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010634292"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.283.15.1967", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011278902"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1017/s0266462309090023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013718223"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.d7995", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014708031"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cvm-1-2-076", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015965085", 
          "https://doi.org/10.1186/cvm-1-2-076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc09-1554", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020235599"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.282.8.790", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027583853"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ceor.s39624", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029697602"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.pharmtox.41.1.347", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031863312"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.38.7571", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033934691"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/14737167.2013.814962", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034190527"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2006.08.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037758979"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11606-007-0453-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040795326", 
          "https://doi.org/10.1007/s11606-007-0453-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11593030-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043242300", 
          "https://doi.org/10.2165/11593030-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jcjd.2013.01.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044492102"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1503/cmaj.070713", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045288123"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1503/cmaj.070713", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045288123"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc10-s011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048430528"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1017/s0266462309990213", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050817627"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200624110-00011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052782401", 
          "https://doi.org/10.2165/00019053-200624110-00011"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1900/rds.2008.5.128", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068727903"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-125-7-199610010-00011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073700886"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-12", 
    "datePublishedReg": "2013-12-01", 
    "description": "BACKGROUND: Surrogate outcomes are a significant challenge in drug evaluation for health technology assessment (HTA) agencies. The research objectives were to: identify factors associated with surrogate use and acceptability in Canada's Common Drug Review (CDR) recommendations, and compare the CDR with other HTA or regulatory agencies regarding surrogate concerns.\nMETHODS: Final recommendations were identified from CDR inception (September 2003) to December 31, 2010. Recommendations were classified by type of outcome (surrogate, final, other) and acceptability of surrogates (determined by the presence/absence of statements of concern regarding surrogates). Descriptive and statistical analyses examined factors related to surrogate use and acceptability. For thirteen surrogate-based submissions, recommendations from international HTA and regulatory agencies were reviewed for statements about surrogate acceptability.\nRESULTS: Of 156 final recommendations, 68 (44%) involved surrogates. The overall 'do not list' (DNL) rate was 48%; the DNL rate for surrogates was 41% (p\u2009=\u20090.175). The DNL rate was 64% for non-accepted surrogates (n\u2009=\u200928) versus 25% for accepted surrogates (odds ratio 5.4, p\u2009=\u20090.002). Clinical uncertainty, use of economic evidence over price alone, and a premium price were significantly associated with non-accepted surrogates. Surrogates were used most commonly for HIV, diabetes, rare diseases, cardiovascular disease and cancer. For the subset of drugs studied, other HTA agencies did not express concerns for most recommendations, while regulatory agencies frequently stated surrogate acceptance.\nCONCLUSIONS: The majority of surrogates were accepted at the CDR. Non-accepted surrogates were significantly associated with clinical uncertainty and a DNL recommendation. There was inconsistency of surrogate acceptability across several international agencies. Stakeholders should consider collaboratively establishing guidelines on the use, validation, and acceptability of surrogates.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1478-7547-11-31", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032048", 
        "issn": [
          "1478-7547"
        ], 
        "name": "Cost Effectiveness and Resource Allocation", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "name": "Surrogate outcomes: experiences at the Common Drug Review", 
    "pagination": "31", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "8895216f75d87e1f30149ca2effc682de395a3b7f6aed0650eea2fa10f26b2b5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24341379"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101170476"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1478-7547-11-31"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1028671719"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1478-7547-11-31", 
      "https://app.dimensions.ai/details/publication/pub.1028671719"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1478-7547-11-31"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1478-7547-11-31'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1478-7547-11-31'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1478-7547-11-31'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1478-7547-11-31'


 

This table displays all metadata directly associated to this object as RDF triples.

170 TRIPLES      21 PREDICATES      53 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1478-7547-11-31 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author Nb4420cd923f14ec497e30c0716096051
4 schema:citation sg:pub.10.1007/s11606-007-0453-4
5 sg:pub.10.1186/cvm-1-2-076
6 sg:pub.10.2165/00019053-200624110-00011
7 sg:pub.10.2165/11593030-000000000-00000
8 https://doi.org/10.1001/jama.2009.1409
9 https://doi.org/10.1001/jama.2012.7961
10 https://doi.org/10.1001/jama.282.8.790
11 https://doi.org/10.1001/jama.283.15.1967
12 https://doi.org/10.1016/j.ejca.2006.08.010
13 https://doi.org/10.1016/j.jcjd.2013.01.014
14 https://doi.org/10.1017/s0266462309090023
15 https://doi.org/10.1017/s0266462309990213
16 https://doi.org/10.1056/nejmoa072761
17 https://doi.org/10.1136/bmj.d7995
18 https://doi.org/10.1146/annurev.pharmtox.41.1.347
19 https://doi.org/10.1200/jco.2011.38.7571
20 https://doi.org/10.1377/hlthaff.25.2.337
21 https://doi.org/10.1503/cmaj.070713
22 https://doi.org/10.1586/14737167.2013.814962
23 https://doi.org/10.1900/rds.2008.5.128
24 https://doi.org/10.2147/ceor.s39624
25 https://doi.org/10.2337/dc09-1554
26 https://doi.org/10.2337/dc10-s011
27 https://doi.org/10.7326/0003-4819-125-7-199610010-00011
28 schema:datePublished 2013-12
29 schema:datePublishedReg 2013-12-01
30 schema:description BACKGROUND: Surrogate outcomes are a significant challenge in drug evaluation for health technology assessment (HTA) agencies. The research objectives were to: identify factors associated with surrogate use and acceptability in Canada's Common Drug Review (CDR) recommendations, and compare the CDR with other HTA or regulatory agencies regarding surrogate concerns. METHODS: Final recommendations were identified from CDR inception (September 2003) to December 31, 2010. Recommendations were classified by type of outcome (surrogate, final, other) and acceptability of surrogates (determined by the presence/absence of statements of concern regarding surrogates). Descriptive and statistical analyses examined factors related to surrogate use and acceptability. For thirteen surrogate-based submissions, recommendations from international HTA and regulatory agencies were reviewed for statements about surrogate acceptability. RESULTS: Of 156 final recommendations, 68 (44%) involved surrogates. The overall 'do not list' (DNL) rate was 48%; the DNL rate for surrogates was 41% (p = 0.175). The DNL rate was 64% for non-accepted surrogates (n = 28) versus 25% for accepted surrogates (odds ratio 5.4, p = 0.002). Clinical uncertainty, use of economic evidence over price alone, and a premium price were significantly associated with non-accepted surrogates. Surrogates were used most commonly for HIV, diabetes, rare diseases, cardiovascular disease and cancer. For the subset of drugs studied, other HTA agencies did not express concerns for most recommendations, while regulatory agencies frequently stated surrogate acceptance. CONCLUSIONS: The majority of surrogates were accepted at the CDR. Non-accepted surrogates were significantly associated with clinical uncertainty and a DNL recommendation. There was inconsistency of surrogate acceptability across several international agencies. Stakeholders should consider collaboratively establishing guidelines on the use, validation, and acceptability of surrogates.
31 schema:genre research_article
32 schema:inLanguage en
33 schema:isAccessibleForFree true
34 schema:isPartOf N3cbbedd3489443c6a0a3c53b7d1712e1
35 N3d2f48858d03468fa29fc3da1a42dfa6
36 sg:journal.1032048
37 schema:name Surrogate outcomes: experiences at the Common Drug Review
38 schema:pagination 31
39 schema:productId N77ca44798aac4a54976db87b6a687950
40 N8c92dcb353be40f18ceb7e9b4c7f4674
41 Nc5c73fef141f4a76b707d6a660d039c7
42 Ndd3247d4b84849d9b6715e5af0ba51e1
43 Nff21692c569b478c980dc4a819822115
44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028671719
45 https://doi.org/10.1186/1478-7547-11-31
46 schema:sdDatePublished 2019-04-10T19:57
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher N2634c78980cf4882a9d4caed55bbf1f4
49 schema:url http://link.springer.com/10.1186%2F1478-7547-11-31
50 sgo:license sg:explorer/license/
51 sgo:sdDataset articles
52 rdf:type schema:ScholarlyArticle
53 N1c01de2d2b3641248018e6756c69826d schema:name Axia Research, 2068 Waterbridge Drive, L7M 3W2, Burlington, ON, Canada
54 rdf:type schema:Organization
55 N2634c78980cf4882a9d4caed55bbf1f4 schema:name Springer Nature - SN SciGraph project
56 rdf:type schema:Organization
57 N304db53cb3484a9683c87b42512c83d0 rdf:first sg:person.01052355256.25
58 rdf:rest rdf:nil
59 N3cbbedd3489443c6a0a3c53b7d1712e1 schema:volumeNumber 11
60 rdf:type schema:PublicationVolume
61 N3d2f48858d03468fa29fc3da1a42dfa6 schema:issueNumber 1
62 rdf:type schema:PublicationIssue
63 N77ca44798aac4a54976db87b6a687950 schema:name pubmed_id
64 schema:value 24341379
65 rdf:type schema:PropertyValue
66 N8c92dcb353be40f18ceb7e9b4c7f4674 schema:name doi
67 schema:value 10.1186/1478-7547-11-31
68 rdf:type schema:PropertyValue
69 Nb41013eb24c143b69abf0846f32c2aa3 rdf:first sg:person.01001154670.78
70 rdf:rest Ncd1f70eaa3f247aaa1b1dfb46e4109dd
71 Nb4420cd923f14ec497e30c0716096051 rdf:first sg:person.01151361731.30
72 rdf:rest Nb41013eb24c143b69abf0846f32c2aa3
73 Nc5c73fef141f4a76b707d6a660d039c7 schema:name nlm_unique_id
74 schema:value 101170476
75 rdf:type schema:PropertyValue
76 Ncd1f70eaa3f247aaa1b1dfb46e4109dd rdf:first sg:person.01245231275.51
77 rdf:rest N304db53cb3484a9683c87b42512c83d0
78 Ndd3247d4b84849d9b6715e5af0ba51e1 schema:name readcube_id
79 schema:value 8895216f75d87e1f30149ca2effc682de395a3b7f6aed0650eea2fa10f26b2b5
80 rdf:type schema:PropertyValue
81 Nff21692c569b478c980dc4a819822115 schema:name dimensions_id
82 schema:value pub.1028671719
83 rdf:type schema:PropertyValue
84 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
85 schema:name Medical and Health Sciences
86 rdf:type schema:DefinedTerm
87 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
88 schema:name Public Health and Health Services
89 rdf:type schema:DefinedTerm
90 sg:journal.1032048 schema:issn 1478-7547
91 schema:name Cost Effectiveness and Resource Allocation
92 rdf:type schema:Periodical
93 sg:person.01001154670.78 schema:affiliation https://www.grid.ac/institutes/grid.25073.33
94 schema:familyName Khoudigian
95 schema:givenName Shoghag
96 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001154670.78
97 rdf:type schema:Person
98 sg:person.01052355256.25 schema:affiliation https://www.grid.ac/institutes/grid.452761.3
99 schema:familyName Goeree
100 schema:givenName Ron
101 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052355256.25
102 rdf:type schema:Person
103 sg:person.01151361731.30 schema:affiliation N1c01de2d2b3641248018e6756c69826d
104 schema:familyName Rocchi
105 schema:givenName Angela
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151361731.30
107 rdf:type schema:Person
108 sg:person.01245231275.51 schema:affiliation https://www.grid.ac/institutes/grid.452761.3
109 schema:familyName Hopkins
110 schema:givenName Rob
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245231275.51
112 rdf:type schema:Person
113 sg:pub.10.1007/s11606-007-0453-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040795326
114 https://doi.org/10.1007/s11606-007-0453-4
115 rdf:type schema:CreativeWork
116 sg:pub.10.1186/cvm-1-2-076 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015965085
117 https://doi.org/10.1186/cvm-1-2-076
118 rdf:type schema:CreativeWork
119 sg:pub.10.2165/00019053-200624110-00011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052782401
120 https://doi.org/10.2165/00019053-200624110-00011
121 rdf:type schema:CreativeWork
122 sg:pub.10.2165/11593030-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043242300
123 https://doi.org/10.2165/11593030-000000000-00000
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1001/jama.2009.1409 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009725452
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1001/jama.2012.7961 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000247836
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1001/jama.282.8.790 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027583853
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1001/jama.283.15.1967 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011278902
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1016/j.ejca.2006.08.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037758979
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1016/j.jcjd.2013.01.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044492102
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1017/s0266462309090023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013718223
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1017/s0266462309990213 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050817627
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1056/nejmoa072761 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010634292
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1136/bmj.d7995 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014708031
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1146/annurev.pharmtox.41.1.347 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031863312
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1200/jco.2011.38.7571 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033934691
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1377/hlthaff.25.2.337 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004154780
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1503/cmaj.070713 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045288123
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1586/14737167.2013.814962 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034190527
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1900/rds.2008.5.128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068727903
156 rdf:type schema:CreativeWork
157 https://doi.org/10.2147/ceor.s39624 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029697602
158 rdf:type schema:CreativeWork
159 https://doi.org/10.2337/dc09-1554 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020235599
160 rdf:type schema:CreativeWork
161 https://doi.org/10.2337/dc10-s011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048430528
162 rdf:type schema:CreativeWork
163 https://doi.org/10.7326/0003-4819-125-7-199610010-00011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073700886
164 rdf:type schema:CreativeWork
165 https://www.grid.ac/institutes/grid.25073.33 schema:alternateName McMaster University
166 schema:name McMaster University, Hamilton, ON, Canada
167 rdf:type schema:Organization
168 https://www.grid.ac/institutes/grid.452761.3 schema:alternateName Programs for Assessment of Technology in Health Research Institute
169 schema:name PATH Research, Hamilton, ON, Canada
170 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...